Nat. Rev. Cardiol. doi: /nrcardio

Slides:



Advertisements
Similar presentations
Date of download: 11/13/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Reality of Heart Failure in Latin America J.
Advertisements

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Life expectancy at birth in all countries included
Figure 7 Mendelian randomization of overlapping exposures
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Effects of adiponectin on podocyte function
Figure 1 Lung and pleural ultrasonography
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Endocrinol. doi: /nrendo
Figure 2 Different manifestations of myocardial ischaemia
Reproduced with permission from Yancy, C. W. et al. 2017
Figure 5 BMI and cardiorespiratory fitness levels
Figure 8 Implanted devices for the management of heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Experimental design
Figure 1 Energy supply–demand matching in health and heart failure
Figure 3 Global rates of sodium, fruit, and vegetable intake
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Size categorization of airborne pollutants
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Endocrinol. doi: /nrendo
Figure 2 Three-year survival rates on the basis of body composition
Figure 2 Physical activity and obesity levels by WHO-designated region and sex Figure 2 | Physical activity and obesity levels by WHO-designated region.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 The burden of chronic kidney disease (CKD)
Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Speckle tracking echocardiography to
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.
Figure 4 Prevalence of HFpEF and HFrEF by age
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Cardiovascular risk and disease across the life-course
Figure 1 Decision tree integrating the assessment,
Figure 2 Global cost of HF per capita in 2012
Figure 2 A patient with aortic stenosis and mitral regurgitation
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Challenges for big data applications in cardiovascular care
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Absolute difference in seasonal peak
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 Observational studies on multiple treatment strategies
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Baseline Characteristics
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Impaired mitochondrial capacity and function in heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.65 Figure 2 Projected population burden of common risk factors for heart failure in the USA Figure 2 | Projected population burden of common risk factors for heart failure in the USA. Projected increases in the population prevalence of hypertension, coronary heart disease, obesity, and type 2 diabetes mellitus4,6,7. Dunlay, S. M. et al. (2017) Epidemiology of heart failure with preserved ejection fraction Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.65